IO

ION Geophysical Corporation

IO

Market cap $10.2M

Delisted

IO was delisted on the 18th of May, 2022.

Back to rankings

About: ION Geophysical Corp is a United States-based technology-focused company, which provides geoscience products, services, and solutions to the global oil and gas industry. The company operates through two segments: E&P Technology & Services and E&P Operations Optimization. It generates the majority of its revenue comes from the Technology & Services segment which creates digital data assets and delivers services to E&P(exploration and production) companies. Its geographical segments are Latin America, North America, Europe, Asia Pacific, Africa, Middle East, and others.

Employees: 360

Communication Services Entertainment

Financial journalist opinion

IMFINZI® (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancer

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive bladder cancer (MIBC). The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available options by demonstrating safety or efficacy improvements, preventing serious cond.

IMFINZI® (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancer

IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. The approval was granted by the Food and Drug Administration (FDA) after securing Priority Review and Breakthrough Therapy Designation. It was based on results from the ADRIATIC Phase III trial which were pr.

IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer

IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC). Patients were treated with IMFINZI in combination.

IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following concurrent chemoradiotherapy (cCRT) compared to placebo after cCRT. Small cell lung cancer (SC.

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

See News Rankings

Charts implemented using Lightweight Charts™